Euroscreen is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs. Euroscreen is developing a pipeline of compounds targeting G protein-coupled receptors (GPCRs) using over 12 years of experience in research and commercialization of this critical class of drug targets in association with the Institute of Interdisciplinary Research (IRIBHM) of the University of Brussels. Functional assay platform is used extensively in its screening of GPCRs for candidate drugs which are partnered during preclinical development.
Euroscreen focuses on innovative targets in internal programs area as well as several partnered preclinical-stage collaborations with biopharmaceutical partners. The company has research and licensing partnerships with Alchemia, Cephalon, GNF, ICOS, Medarex, Novartis and Pfizer Inc.
In addition, he Company has developed a broad patent portfolio of innovative targets for licensing to biopharmaceutical companies. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through the above-mentioned targets.
Euroscreen pursues a dual platform strategy of combining its drug discovery activities with its services business supporting biopharmaceutical companies around the world. Following the recent divestiture of its Products Business to PerkinElmer Life and Analytical Sciences, Euroscreen's commercial activities are now focused on EuroSCREEN FAST for the screening of compounds modulating GPCRs as well as custom services for GPCR assay development and functional antibodies. These custom services capabilities are available by fee-for-service collaborations and as discovery partnerships.
rue A. Bolland 47